Floatz logo

Fluciclovine

Ovarian Epithelial Cancer

Bital Savir-BaruchradiopharmaceuticalPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

245 Active assets in the Ovarian Epithelial Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Trabectedin
AGO Research GmbH
Phase 4BBB
Carboplatin
University of Washington
Phase 3BB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Fluciclovine is also rated in:

metastatic prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →